Quantum Biopharma Ltd. (NASDAQ:QNTM) Short Interest Down 44.5% in December

Quantum Biopharma Ltd. (NASDAQ:QNTM) was the recipient of a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 67,767 shares, a decline of 44.5% from the November 30th total of 122,202 shares. Based on an average daily volume of 75,046 shares, the short-interest ratio is presently 0.9 days. Currently, 1.9% of the company’s shares are short sold. Currently, 1.9% of the company’s shares are short sold. Based on an average daily volume of 75,046 shares, the short-interest ratio is presently 0.9 days.

Quantum Biopharma Stock Down 3.1%

Shares of QNTM traded down $0.26 during trading hours on Monday, reaching $8.04. 55,103 shares of the company traded hands, compared to its average volume of 821,575. The business has a fifty day moving average price of $9.71 and a 200-day moving average price of $16.28. Quantum Biopharma has a 12-month low of $2.89 and a 12-month high of $38.25. The stock has a market capitalization of $30.68 million, a P/E ratio of -0.74 and a beta of 0.15.

Quantum Biopharma (NASDAQ:QNTM) last issued its earnings results on Friday, November 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($1.05). As a group, research analysts predict that Quantum Biopharma will post -3.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Quantum Biopharma

A hedge fund recently bought a new stake in Quantum Biopharma stock. Steward Partners Investment Advisory LLC purchased a new stake in shares of Quantum Biopharma Ltd. (NASDAQ:QNTM) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 3,100 shares of the company’s stock, valued at approximately $63,000. Steward Partners Investment Advisory LLC owned approximately 0.11% of Quantum Biopharma at the end of the most recent quarter. 1.24% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Quantum Biopharma in a research note on Monday, December 22nd. Wall Street Zen upgraded Quantum Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Quantum Biopharma has an average rating of “Sell”.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.